跳到正文
Mario Balsa· @MarioBalsaMD · X·· 22 小时前评分45

#OAONTHEGO

正文 · 原文

🎬 Loved kicking off #OAOnTheGo at #ESMO26 with a topic that rarely fits neatly into trial eligibility criteria!

Pregnancy, transplantation, immunosuppression…the hardest part of immunotherapy is understanding the patient around it!

Thanks @OncoAlert for everything! 🖤

@OncoReporte @myESMO @_SEOM @GrupoMelanoma

@hospitalclinic
#ClínicBarcelonaComprehensiveCancerCenter

43 浏览 · 1 赞 · 1 转发 · 0 回复

引用@
🎬 New #OAOnTheGo 🎥 from #ESMO26 Our #OncoAlertAF colleagues & Melanoma specialist Dr. @MarioBalsaMD (Hospital Clínic Barcelona) on treating patients who don’t fit the trials: 🤰 Melanoma in pregnancy: very limited data, and none at all for anti-LAG3 Transplant recipients: checkpoint inhibitors can work, but rejection occurs in ~1 in 3 Immunotherapy is never just about the tumor 👇 #ESMO26 #Melanoma @DrBetofMDPhD @cdanicas, @matteolambe, @NiuSanford, @GlopesMd, @PGrivasMDPhD, @brian_rini, @to_be_elizabeth, @ElisaAgostinett, @nataliagandur, @UOzkerim, @DrMirallas, @DrYukselUrun, @Lucarecco, @mzugman, @HHorinouchi, @p_ciracimd, @DraMartinezLago, @DrVilmaPBarcia, @GIMedOnc, @MarioBalsaMD, @scocmem, @AmandaNizamMD, @GaiaGriguolo, @JankovicK, @Dr_Oncologista, @Erman_Akkus, @WeOncologists, @niklas_kluemper, @Markuseckstein
在 X 查看被引用的帖子

来源:Mario Balsa · x.com

CBACBA Frontier Insights (CFI)美国华人生物医药科技协会(CBA)www.cba-usa.org